Johnson & Johnson acquires Proteologix, atopic dermatitis portfolio
Click Here to Manage Email Alerts
Key takeaways:
- Proteologix’s lead product, PX128, is an IL-13 and thymic stromal lymphopoietin mediator in development for atopic dermatitis and asthma.
- Johnson & Johnson will pay $850 million in the transaction.
Johnson & Johnson will pay $850 million to acquire the biotechnology company Proteologix Inc., the company announced in a press release.
Proteologix’s portfolio includes bispecific antibodies for immune-mediated diseases, including PX128, currently entering phase 1 development for atopic dermatitis and asthma, and PX130, currently in preclinical development for atopic dermatitis, as well as other bispecific antibody programs.
PX128 inhibits both interleukin-13-mediated Th2 skin inflammation and thymic stromal lymphopoietin, a mediator of tissue inflammation, whereas PX130 is an IL-13 and IL-22 inhibitor that aims to restore the skin barrier and prevent inflammation, according to the release.
“Integrating Proteologix bispecific antibodies into our pipeline is an important first step in fulfilling our commitment to people living with AD,” Candice Long, worldwide vice president, immunology, Johnson & Johnson, said in the release. “We plan to continue expanding our reach and impact for people living with a wide variety of immune-mediated diseases, leveraging more targeted options for them to reach durable, symptom-free remission.”
The acquisition, scheduled to close mid-year 2024, is not expected to impact Johnson & Johnson’s 2024 adjusted earnings per share guidance range.
Read more about
Click Here to Manage Email Alerts